KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties
Maria Cristina Cioclu,Ilaria Mosca,Paolo Ambrosino,Deborah Puzo,Allan Bayat,Saskia B Wortmann,Johannes Koch,Vincent Strehlow,Kentaro Shirai,Naomichi Matsumoto,Stephan J Sanders,Vincent Michaud,Marine Legendre,Antonella Riva,Pasquale Striano,Hiltrud Muhle,Manuela Pendziwiat,Gaetan Lesca,Giuseppe Donato Mangano,Rosaria Nardello,KCNT2-study group,Johannes R Lemke,Rikke S Møller,Maria Virginia Soldovieri,Guido Rubboli,Maurizio Taglialatela,Ilenio Servettini,Giorgio Belperio,Erik-Jan Kamsteeg,Koji Takahashi,Satomi Mitsuhashi,Elizabeth E Palmer,Ann M Bye,Irene Madrigal,Maria Isabel Alvarez-Mora,Aurora Sánchez,Stefano Meletti,Ingo Helbig,Pauline Le Tanno,Bénédicte Gerard,Salima El Chehadeh
DOI: https://doi.org/10.1002/ana.26662
Abstract:Objective: Pathogenic variants in KCNT2 are rare causes of developmental epileptic encephalopathy (DEE). We herein describe the phenotypic and genetic features of patients with KCNT2-related DEE, and the in vitro functional and pharmacological properties of KCNT2 channels carrying 14 novel or previously untested variants. Methods: Twenty-five patients harboring KCNT2 variants were investigated: 12 were identified through an international collaborative network, 13 were retrieved from the literature. Clinical data were collected and included in a standardized phenotyping sheet. Novel variants were detected using exome sequencing and classified using ACMG criteria. Functional and pharmacological studies were performed by whole-cell electrophysiology in HEK-293 and SH-SY5Y cells. Results: The phenotypic spectrum encompassed: (a) intellectual disability/developmental delay (21/22 individuals with available information), ranging from mild to severe/profound; (b) epilepsy (15/25); (c) neurological impairment, with altered muscle tone (14/22); (d) dysmorphisms (13/20). Nineteen pathogenic KCNT2 variants were found (9 new, 10 reported previously): 16 missense, 1 in-frame deletion of a single amino acid, 1 nonsense, and 1 frameshift. Among tested variants, 8 showed gain-of-function (GoF), and 6 loss-of-function (LoF) features when expressed heterologously in vitro. Quinidine and fluoxetine blocked all GoF variants, whereas loxapine and riluzole activated some LoF variants while blocking others. Interpretation: We expanded the phenotypic and genotypic spectrum of KCNT2-related disorders, highlighting novel genotype-phenotype associations. Pathogenic KCNT2 variants cause GoF or LoF in vitro phenotypes, and each shows a unique pharmacological profile, suggesting the need for in vitro functional and pharmacological investigation to enable targeted therapies based on the molecular phenotype. ANN NEUROL 2023;94:332-349.